NEO100
Phase 2Small molecule
NEO100 is one of 20 small molecule programs targeting Meningioma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Meningioma
#DrugCompanyPhaseTrials
1Cyklokapron
JJ Molner
Approved
Signifor
RRECORDATI GROUP
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Keytruda
Merck & Co.Phase 2
Afinitor
NovartisPhase 2
Cabometyx
Bristol-Myers SquibbPhase 2
Verzenio
Eli LillyPhase 2
Lutathera
AAdvanced Accelerator Applications
Phase 2
Lutathera
NovartisPhase 2
Zanzalintinib
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NEO100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNeonc Technologies, Inc.